"To date, biosimilars have not
really impacted the rheumatoid arthritis space. It varies with payers, but
Remicade has held its own so far this year....[But] we expect the biosimilars
to get much better placement on formularies for 2018."
— Daniel Kus, B.S.Pharm., R.Ph.,
vice president at Pharmacy Advantage Specialty Pharmacy, and Katherine Lewnau,
Pharm.D., autoimmune specialist at the company, tell Radar on Specialty Pharmacy.
No comments:
Post a Comment